In 2019, 5 out of 20 first-in-class approved therapeutic agents targeted GPCRs. high number of GPCR targeted drugs, only a small portion (∼110) of the human GPCRome (consisting of approximately

April 2022 "By Sophie Bradley | Apr 12, 2022 Summary Sophie Bradley, Translational Sciences Associate

May 2022 "Seoul, South Korea, 28 April 2022 – GPCR therapeutics , Inc., a venture-backed clinical stage international biopharmaceutical company with an innovative approach to drug discovery based on targeting G Protein Coupled Receptors (GPCR) pairs, today announced four appointments to its Scientific Advisory

April 2022 John Streicher talks about his work on terpenes found in cannabis as these may be a novel

April 2022 Trevena Announces Receipt of First $15 million Tranche in Connection with its $40 million ex-US Royalty-Based Financing with R-Bridge Healthcare Fund " CHESTERBROOK, Pa., April 18, 2022 - Trevena

April 2022 Trevena Receives up to $40M in OLINVYK ex-US Royalty-Based Financing from R-Bridge Healthcare

April 2022 "By Cliona MacSweeney | Apr 20, 2022 Cliona MacSweeney, a project director in our Translational

April 2022 Read more at the source #DrGPCR #GPCR #IndustryNews

April 2022 Sosei Heptares Confirms Senior Leadership Changes to Drive the Company Through the Next Stage platform and enhancing translational medicine capabilities • ‘Venture-like’ capital allocation approach Chris Cargill appointed as President and Chief Executive Officer • Dr. Matt Barnes appointed President of Heptares Therapeutics Ltd., and Head of UK R&D Tokyo, Japan and Corporation (“the Company”; TSE: 4565) today confirms that a series of Executive Management changes have been approved

April 2022 Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of Ultrahigh Throughput Drug Discovery Platform " April 12, 2022 07:00 AM Eastern Daylight Time CAMBRIDGE

April 2022 Addex Expands Pipeline With Selective M4 Positive Allosteric Modulator Program For The Treatment Allosteric Modulator Screening Platform Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April

April 2022 Addex Therapeutics Completes Patient Enrollment For Dipraglurant Blepharospasm Phase 2 Clinical Study " Geneva, Switzerland, April 13, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage

April 2022 "SAN DIEGO, April 12, 2022 — Crinetics Pharmaceuticals , Inc. deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately The offering is expected to close on or about April 18, 2022, subject to the satisfaction of customary

Explicyte , an expert in the field of IO and innovative target identification through multiparametric approaches

CFTX-1554 is being developed as a non-opioid approach to the treatment of neuropathic pain, a debilitating

You can also leave us a review on Apple Podcast!

It captures our values and vision for the future, our culture, and our unique approach to science.

improve the folding and stability of the mutant receptor is one of the most promising pharmacological approaches

development and wing expansion and maturation in H. cunea, suggesting HLGR2 is a promising candidate for application

mechanical and/or pharmacological activation of endogenous Ca2+ signaling transducers; however, such approaches

Applying this molecular tool in a membrane-based setup and in living cells, we discovered a 4-aminopyrimidine succeeded in showing that our CCR9-PROTAC is able to reduce CCR9 levels, thereby offering an unprecedented approach

receptors (GPCRs), a large class of signaling proteins exemplified by the visual receptor rhodopsin and its apoprotein

located at cognate positions across GPCR paralogs opens a window into cancer mechanisms and potential approaches

Although several GPCRs have been studied in astrocytes using a chemogenetic approach, the functional

With appreciable D2LR and D4R agonism and D1R antagonism, kurarinone might be a potential compound that

Specifically controlling the activity of GPCR dimers with ligands is a good approach to clarify their

acute metabolic effects following agonist activation of β2-adrenergic and, potentially, CRF2 receptors appear

Microiontophoretically applied H1152, a ROCK inhibitor, and siRNA-induced ROCK2 knockdown both depressed